Table 1.
Patient clinical and laboratory characteristics.
| Short DTI (0-22 days) | Long DTI (over 22 days) | All patients | p | |
|---|---|---|---|---|
| (n = 102) | (n = 97) | (n = 199) | ||
| Men/women | 51/51 | 50/47 | 101/98 | NS |
| Age (mean) | 70 | 66 | 70 | 0.01 |
| PS 2–4 | 46 (45%) | 12 (12%) | 58 (29%) | < 0.001 |
| B symptoms | 33 (32%) | 15 (15%) | 48 (24%) | 0.007 |
| Serum albumin (mean, g/dl) | 3.2 | 3.6 | 3.4 | < 0.001 |
| LDH > ULN | 86 (84%) | 64 (66%) | 150 (75%) | 0.003 |
| Ann Arbor stage III–IV | 79 (77%) | 56 (58%) | 135 (68%) | 0.004 |
| Extranodal lesions | 71 (70%) | 60 (62%) | 131 (66%) | NS |
| Bulky lesion | 19 (19%) | 16 (16%) | 35 (18%) | NS |
| IPI 3–5 | 74 (73%) | 45 (46%) | 119 (60%) | < 0.001 |
| Diagnosed in other facilities | 12 (12%) | 19 (20%) | 31 (16%) | NS |
| Treatment | ||||
| CHOP based | 44 (43%) | 52 (54%) | 96 (48%) | NS |
| THP-COP based | 58 (57%) | 45 (46%) | 103 (52%) | NS |
| Rituximab | 95 (93%) | 92 (95%) | 187 (94%) | NS |
PS performance status, LDH lactate dehydrogenase, ULN upper limit of normal, IPI International Prognostic Index.